Integrating AI and Pathway Flexibility to Advance Value-Based Cancer Care: Clayton Irvine, PharmD, MBA, MS

Clayton Irvine, PharmD, MBA, MS, discusses strategies to address payer-driven biosimilar and prior authorization challenges through integrated digital solutions, while advocating for flexible, regularly reviewed treatment pathways supported by molecular tumor boards and artificial intelligence to balance standardization with personalized, biomarker-driven oncology care.